Please login to the form below

Not currently logged in
Email:
Password:

Cancer Drugs Fund

This page shows the latest Cancer Drugs Fund news and features for those working in and with pharma, biotech and healthcare.

Gilead strikes deal with NHS England on CAR-T Yescarta

Yescarta has a UK list price of nearly £300, 000 per patient, but the company’s commercial agreement with NHS England has now led to NICE approval via the Cancer Drugs ... the chimeric antigen receptor (CAR), and then reinfused back into the patient

Latest news

  • Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness

    trace of the cancer left – offering hope of a long term remission or even a cure. ... Gilead’s managing director for the UK and Ireland Hilary Hutton-Squire told PME that she is confident of agreeing a deal, with access via the Cancer Drugs Fund (CDF)

  • NICE turns down Opdivo for adjuvant melanoma therapy NICE turns down Opdivo for adjuvant melanoma therapy

    It also says it cannot recommend the drug for use within the Cancer Drugs Fund (CDF) “because… it is not possible to assess whether nivolumab has plausible potential to be cost ... effective.”For the last couple of years NICE has called the shots

  • Gilead optimistic about Yescarta deal in UK Gilead optimistic about Yescarta deal in UK

    Gilead has been in talks with NICE, its ‘managed access’Cancer Drugs Fund (CDF) committee and specialised medicines budget holder NHS England for many months in the run-up to the ... Meanwhile, the immature data makes using the Cancer Drugs Fund the

  • Novartis’ CAR-T Kymriah gets green light in England Novartis’ CAR-T Kymriah gets green light in England

    The money for Kymriah (tisagenlecleucel) will come from the Cancer Drugs Fund (CDF). ... Adult patients with another cancer approved for treatment using Kymriah – diffuse large B cell lymphoma (DLBCL) – will have to wait to hear guidance from NICE,

  • It’s a no for Yescarta, says NICE on heels of EU approval It’s a no for Yescarta, says NICE on heels of EU approval

    T Yescarta, rejecting use of the cancer immunotherapy by the NHS in draft guidance. ... While it is a life-extending treatment, Yescarta doesn’t meet NICE’s criteria for cost-effectiveness for NHS use or indeed the Cancer Drugs Fund (CDF), coming in

More from news
Approximately 48 fully matching, plus 112 partially matching documents found.

Latest Intelligence

  • 30 Women Leaders in UK Healthcare

    A very notable victory has just been announced, with Keytruda becoming the first of the groundbreaking immunotherapy drugs to exit the Cancer Drugs Fund and secure NICE approval for first-line ... pharma’to become chief executive of Redx, a promising

  • Uncertainty, austerity and Brexit Uncertainty, austerity and Brexit

    Companies have seen repeated attempts by the Government and NHS England to prevent patients from accessing new medicines, from the controversial reforms to the Cancer Drugs Fund to the ‘run

  • Opening up market access Opening up market access

    In this PME market access supplement we look at the direction of travel in France and Germany and there’ s an introduction to the UK’ s new-look Cancer Drugs Fund.

  • Opening up market access Opening up market access

    In this PME market access supplement we look at the direction of travel in France and Germany and there’ s an introduction to the UK’ s new-look Cancer Drugs Fund.

  • Stepping up to payer-driven market access Stepping up to payer-driven market access

    products. In the UK, for instance, NICE now regulates access to the Cancer Drugs Fund, and products will need to meet NICE thresholds in order to be reimbursed.

More from intelligence
Approximately 2 fully matching, plus 14 partially matching documents found.

Latest appointments

  • New health ministers and re-appointments after reshuffle New health ministers and re-appointments after reshuffle

    Freeman's role is also tied into the Department for Business, Innovation and Skills and includes expanded responsibility for the Cancer Drugs Fund, NICE and MHRA, research and development, issues around ... the uptake of new drugs and med tech, and the

  • Celgene names general manager for UK and Ireland Celgene names general manager for UK and Ireland

    This is even more pertinent with the recent changes to the Cancer Drugs Fund, which I strongly hope will enable patients with myeloma and metastatic pancreatic cancer to continue to be

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics